Dimensional Fund Advisors LP Purchases 122,718 Shares of Core Laboratories Inc. $CLB

Dimensional Fund Advisors LP raised its position in shares of Core Laboratories Inc. (NYSE:CLB) by 10.0% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 1,352,329 shares of the oil and gas company’s stock after purchasing an additional 122,718 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Core Laboratories were worth $22,705,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. Summit Securities Group LLC purchased a new position in shares of Core Laboratories in the first quarter valued at about $31,000. Aster Capital Management DIFC Ltd bought a new position in shares of Core Laboratories during the fourth quarter valued at about $34,000. Quarry LP boosted its holdings in shares of Core Laboratories by 118.1% during the third quarter. Quarry LP now owns 2,953 shares of the oil and gas company’s stock worth $36,000 after purchasing an additional 1,599 shares during the period. CWM LLC boosted its holdings in shares of Core Laboratories by 36.1% during the fourth quarter. CWM LLC now owns 2,516 shares of the oil and gas company’s stock worth $40,000 after purchasing an additional 668 shares during the period. Finally, Hantz Financial Services Inc. grew its stake in shares of Core Laboratories by 124.7% in the fourth quarter. Hantz Financial Services Inc. now owns 3,177 shares of the oil and gas company’s stock worth $51,000 after purchasing an additional 1,763 shares during the last quarter. Institutional investors own 97.81% of the company’s stock.

Core Laboratories Stock Up 2.2%

Shares of NYSE CLB opened at $11.20 on Friday. The firm has a fifty day simple moving average of $11.76 and a two-hundred day simple moving average of $14.97. Core Laboratories Inc. has a 12 month low of $9.72 and a 12 month high of $20.36. The company has a current ratio of 2.12, a quick ratio of 1.55 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $513.68 million, a PE ratio of 19.99, a price-to-earnings-growth ratio of 2.64 and a beta of 1.03.

Core Laboratories (NYSE:CLB) last announced its earnings results on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The firm had revenue of $124.61 million for the quarter, compared to analyst estimates of $126.26 million. During the same quarter in the previous year, the firm posted $0.19 EPS. The company’s revenue for the quarter was down 4.3% compared to the same quarter last year. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. Equities analysts expect that Core Laboratories Inc. will post 0.53 earnings per share for the current year.

Core Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Monday, August 10th will be issued a $0.01 dividend. The ex-dividend date is Monday, August 10th. This represents a $0.04 annualized dividend and a yield of 0.4%. Core Laboratories’s dividend payout ratio (DPR) is 7.14%.

Insiders Place Their Bets

In other news, CEO Lawrence Bruno acquired 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The shares were acquired at an average cost of $10.78 per share, with a total value of $53,900.00. Following the transaction, the chief executive officer owned 262,438 shares in the company, valued at $2,829,081.64. The trade was a 1.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.26% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on CLB shares. Wall Street Zen raised Core Laboratories from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Weiss Ratings upgraded Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat, the stock currently has a consensus rating of “Hold”.

Core Laboratories Company Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.